Purevax Rabies

RSS

rabies recombinant canarypox virus (vCP65)

Authorised
This medicine is authorised for use in the European Union.

Overview

Purevax Rabies is a veterinary vaccine used to protect cats from 12 weeks of age against rabies infection. It contains rabies recombinant canarypox virus (vCP65).

This EPAR was last updated on 17/02/2021

Authorisation details

Product details
Name
Purevax Rabies
Agency product number
EMEA/V/C/002003
Active substance
vCP65 virus
International non-proprietary name (INN) or common name
rabies recombinant canarypox virus (vCP65)
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AX
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
18/02/2011
Contact address

55216 Ingelheim am Rhein
Germany

Product information

14/08/2020 Purevax Rabies - EMEA/V/C/002003 - IG/1279

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.

Onset of immunity: 4 weeks after the primary vaccination course.

Duration of immunity after primary vaccination: 1 year.

Duration of immunity after revaccination: 3 years.

Assessment history

How useful was this page?

Add your rating
Average
1 rating